ヨーロッパ間質性膀胱炎市場、重症度別（軽度から中等度、中等度から重度）、治療タイプ別（薬物療法、膀胱点滴、ボツリヌス毒素A、神経刺激療法手術）、投与経路別（経口、非経口、膀胱内、局所、その他）、購入方法別（市販薬、処方薬）、患者タイプ別（小児および成人）、エンドユーザー別（病院、診療所、在宅医療、その他）、流通チャネル別（直接入札、小売販売、その他） - 2029年までの業界動向および予測。
ヨーロッパ間質性膀胱炎市場の分析と規模
間質性膀胱炎 (IC) と呼ばれる膀胱痛の症状は、原因不明の膀胱と骨盤底の持続的な痛みを引き起こします。これは女性泌尿器持続性骨盤不快感症候群として知られています。すぐに頻繁に排尿したいという症状があります。生活の質の低下やうつ病は IC/BPS に関連しています。罹患した人の多くは線維筋痛症や過敏性腸症候群にも苦しんでいます。
ヨーロッパの間質性膀胱炎市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に9.7%のCAGRで成長し、2029年までに5億5,619万米ドルに達すると予測しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019-2014 にカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
重症度（軽度から中等度、中等度から重度）、治療タイプ（薬物療法、膀胱点滴、ボツリヌス毒素A、神経刺激療法、手術）、投与経路（経口、非経口、膀胱内、局所、その他）、購入方法（市販薬、処方薬）、患者タイプ（小児および成人）、エンドユーザー（病院、診療所、在宅医療、その他）、流通チャネル（直接入札、小売販売、その他） |
|
対象国 |
ドイツ、イギリス、フランス、イタリア、スペイン、トルコ、ロシア、オランダ、スイス、ベルギー、その他のヨーロッパ諸国。 |
|
対象となる市場プレーヤー |
Alvogen、Janssen Pharmaceuticals、Inc.、Sandoz AG、Sun Pharmaceutical Industries Ltd.、Accord Healthcare US、Avet Pharmaceuticals Inc.、Lannett、Viatris Inc.、Pfizer、Inc.、Strides Pharma Science Limited、GSK plc、Prestige Consumer Healthcare Inc.、Amneal Pharmaceuticals LLC、Zydus Pharmaceuticals、Inc.、Apotex Inc.、Aurobindo Pharma USA、VistaPharm、Inc.、Dr. Reddy's Laboratories、Inc.、Teva Pharmaceuticals USA、Inc.、Bayer AG、Reckitt Benckiser Group PLC など。 |
市場の定義
間質性膀胱炎として知られる持続的な病気は、膀胱の圧迫感、膀胱の痛み、骨盤痛を引き起こします。軽度の不快感から重度の苦痛まで、あらゆる痛みのレベルがあります。この障害は、膀胱痛症候群と呼ばれる病気のグループに属します。医師は、X線検査、尿検査、膀胱鏡を使用した膀胱壁検査など、さまざまな検査を行って膀胱痛障害を診断します。膀胱痛障害は、頻尿や持続的な尿意切迫感など、少なくとも1つの他の排尿症状を伴い、6か月以上続く膀胱に関連していると思われる痛み、圧迫感、不快感が特徴です。これらの膀胱障害は、一般に膀胱炎と呼ばれる膀胱の炎症を引き起こします。障害の治療は、問題の原因によって異なります。重症例では、薬物療法や手術が行われる場合があります。
間質性膀胱炎市場の動向
このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらはすべて、以下のように詳細に説明されます。
ドライバー
-
間質性膀胱炎（IC）の罹患率の増加
間質性膀胱炎（IC）として知られる疾患は、膀胱不快感症候群としても知られ、慢性または長期にわたり、不快な排尿症状を引き起こします。IC の患者は、さまざまな症状を経験する可能性があります。たとえば、骨盤領域にほとんど圧迫感、痛み、または不快感を感じない人もいます。また、ひどい膀胱痛、尿意切迫感（突然の排尿の必要性）、頻尿（より頻繁に排尿したいという欲求）に悩まされる人もいます。間質性膀胱炎市場の成長率に影響を与える主な要因の 1 つは、今日、間質性膀胱炎の罹患率が高まっていることです。女性は特にこの症状に悩まされています。一般的な副作用には、アレルギー、線維筋痛、子宮内膜症などがあります。頻尿、尿意切迫感、骨盤痛は、日中と夜間の両方で発生する可能性のある間質性膀胱炎の臨床症状です。
-
医療費の増加
各国で人々の可処分所得が増加したため、医療費は世界的に上昇しています。さらに、政府機関や医療提供者は、国民のニーズを満たすために医療費の支出を増やすという取り組みを主導しています。
例えば、
-
2020年12月の世界保健機関（WHO）の報告書によると、世界の医療費は2016年の7.6兆米ドルから2018年には8.3兆米ドルに増加し、GDP（国民1人当たり1.080米ドル）の約10％に達した。さらに、世界の医療費は2000年から2017年の間に3.9％増加した。
医療費の増加は、経済成長と医療部門の成長にも寄与しています。これは主に、市場におけるより優れた先進的な医療製品の開発に大きく影響するため、有益です。そのため、医療費の急増は、ヨーロッパの間質性膀胱炎市場の推進力となることが期待されています。
機会
-
医療システムの改善
間質性膀胱炎または膀胱痛症候群は、膀胱に関連する慢性骨盤痛症候群です。膀胱に関連すると思われる痛み、圧迫感、不快感が 6 か月以上続き、頻尿や持続的な尿意切迫感などの他の排尿症状が少なくとも 1 つあるのが特徴です。したがって、膀胱痛の 1 つ以上の症状の改善は、残尿や膀胱過伸展の改善に特に効果的です。
世界中で感染症が増加しているため、発展途上地域ではさまざまな感染症の診断のためのより優れた医療システムの構築が求められています。発展途上地域での医療システムの改善は、予測期間中の市場の成長を促進する可能性があります。
これらの啓発プログラムは、人々が適切な時期に適切な治療法を理解するのに役立ちました。この啓発の高まりにより、消費者は年齢やその効能に応じて新しい治療法を選択できるようになり、さまざまな種類の製品の売上が向上します。したがって、より良いヘルスケア システムの改善は、予測期間中にヨーロッパの間質性膀胱炎市場の成長の機会として機能することが期待されます。
制約/課題
しかし、一部の地域では、間質性膀胱炎治療技術への障壁や治療プロセスの高コストが間質性膀胱炎治療の成長を妨げ、市場の成長を阻害する可能性があります。さらに、医療技術業界における激しい競争や海外での資格取得に長い時間がかかることも、市場の成長にとって課題となる要因です。
この間質性膀胱炎市場レポートでは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場成長、アプリケーションのニッチと優位性、製品承認、製品発売、地理的拡張、市場における技術革新などの詳細を提供します。肺がん手術市場に関する詳細情報を取得するには、アナリスト ブリーフについて Data Bridge Market Research にお問い合わせください。当社のチームは、市場成長を達成するための情報に基づいた市場決定を行うお手伝いをします。
最近の開発
- 2020年7月、UCBとフェリング・ファーマシューティカルズは、間質性膀胱炎治療薬「CIMZIA」のプレフィルドシリンジ製剤を商品化するための共同プロモーション契約を締結したことを発表しました。
- キョーリン製薬ホールディングス株式会社の100％子会社である杏林製薬株式会社は、2021年4月に間質性膀胱炎治療剤「ジムソ膀胱内液50％」を発売しました。
ヨーロッパ間質性膀胱炎市場の範囲
The Europe interstitial cystitis market is segmented into severity, treatment type, route of administration, mode of purchase, patient type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Severity
- Mild To Moderate
- Moderate To Severe
On the basis of severity, the Europe interstitial cystitis market is segmented into mild to moderate and moderate to severe.
Treatment Type
- Medications
- Bladder Instillation
- Botulinum Toxin A
- Nerve Stimulation
- Surgery
On the basis of treatment type, the Europe interstitial cystitis market is segmented into medications, bladder instillation, botulinum toxin A, nerve stimulation and surgery.
Route of Administration
- Oral
- Parenteral
- Intravesical
- Topical
- Others
On the basis of route of administration, the Europe interstitial cystitis market is segmented into oral, parenteral, intravesical, topical and others.
Mode of Purchase
- Over the counter
- Prescription
On the basis of mode of purchase, the Europe interstitial cystitis market is segmented into over the counter and prescription.
Patient Type
- Pediatric
- Adults
On the basis of patient type, the Europe interstitial cystitis market is segmented into paediatric and adults.
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
On the basis of end user, the Europe interstitial cystitis market is segmented into hospitals, clinics, home healthcare and others.
Distribution Channel
- Direct tender
- Retail sales
- Others
On the basis of distribution channels, the Europe interstitial cystitis market is segmented into direct tender, retail sales and others.
Interstitial Cystitis Market Regional Analysis/Insights
The interstitial cystitis market is analyzed, and market size insights and trends are provided by country, severity, treatment type, route of administration, mode of purchase, patient type, end user, and distribution channel, as referenced above.
The interstitial cystitis market comprises of the countries Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.
Germany dominates the Europe interstitial cystitis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising need for the verification and validation of interstitial cystitis treatment processes in the region, and rapid research development is boosting the market.
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。
競争環境と間質性膀胱炎の市場シェア分析
間質性膀胱炎市場の競争環境は、競合他社による詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。上記のデータ ポイントは、間質性膀胱炎市場への企業の焦点にのみ関連しています。
間質性膀胱炎市場で活動している主要企業としては、Alvogen、Janssen Pharmaceuticals、Inc.、Sandoz AG、Sun Pharmaceutical Industries Ltd、Accord Healthcare US、Avet Pharmaceuticals Inc.、Lannett、Viatris Inc.、Pfizer、Inc.、Strides Pharma Science Limited、GSK plc、Prestige Consumer Healthcare Inc.、Amneal Pharmaceuticals LLC、Zydus Pharmaceuticals 、Inc.、Apotex Inc.、Aurobindo Pharma USA、VistaPharm、Inc.、Dr. Reddy's Laboratories、Inc.、Teva Pharmaceuticals USA、Inc.、Bayer AG、Reckitt Benckiser Group PLC などがあります。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、ヨーロッパと地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE INTERSTITIAL CYSTITIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET
4.4 EPIDEMIOLOGY
5 EUROPE INTERSTITIAL CYSTITIS MARKET: REGULATIONS
5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES
5.3 JAPAN REGULATORY GUIDANCE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
6.1.2 RISE IN HEALTHCARE EXPENDITURE
6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS
6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY
6.1.5 RISING DISEASE MANAGEMENT PROGRAMS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS
6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS
6.2.3 DEARTH OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO
6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES
6.3.3 IMPROVING HEALTHCARE SYSTEM
6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.4.2 PATENT EXPIRY OF DRUGS
7 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY
7.1 OVERVIEW
7.2 MILD TO MODERATE
7.3 MODERATE TO SEVERE
8 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANALGESICS
8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
8.2.1.1.1 IBUPROFEN
8.2.1.1.2 NAPROXEN
8.2.1.1.3 OTHERS
8.2.1.2 ACETAMINOPHEN
8.2.1.3 NON-NARCOTIC PAIN MEDICATION
8.2.1.3.1 METHENAMINE
8.2.1.3.2 PHENAZOPYRIDINE
8.2.1.3.3 OTHERS
8.2.1.4 NARCOTIC PAIN MEDICATION
8.2.1.4.1 CODEINE
8.2.1.4.2 HYDROCODONE
8.2.1.4.3 OXYCODONE
8.2.1.4.4 OXYMORPHONE
8.2.1.4.5 MORPHINE
8.2.1.4.6 HYDROMORPHONE
8.2.1.4.7 METHADONE
8.2.1.4.8 OTHERS
8.2.2 ANTIHISTAMINES
8.2.2.1 LORATADINE
8.2.2.2 HYDROXYZINE
8.2.2.3 OTHERS
8.2.3 TRICYCLIC ANTIDEPRESSANTS
8.2.3.1 AMITRIPTYLINE
8.2.3.2 IMIPRAMINE
8.2.3.3 OTHERS
8.2.4 IMMUNOSUPPRESSANTS
8.2.4.1 CYCLOSPORINE
8.2.4.2 MYCOPHENOLATE
8.2.4.3 OTHERS
8.2.5 PENTOSAN POLYSULFATE SODIUM
8.2.6 OTHERS
8.2.6.1 ALPHA BLOCKERS
8.2.6.1.1 DOXAZOSIN
8.2.6.1.2 TERAZOSIN
8.2.6.1.3 TAMSULOSIN
8.2.6.1.4 OTHERS
8.2.6.2 AMPHETAMINES
8.2.6.3 LEUKOTRIENE INHIBITORS
8.2.6.3.1 MONTELUKAST
8.2.6.3.2 ZAFIRLUKAST
8.2.6.3.3 OTHERS
8.2.6.4 OTHERS
8.3 BLADDER INSTILLATIONS
8.3.1 DIMETHYL SULFOXIDE
8.3.2 HEPARIN
8.3.3 OTHERS
8.4 BOTULINUM TOXIN A
8.5 SURGERY
8.5.1 FULGURATION
8.5.2 RESECTION
8.5.3 BLADDER AUGMENTATION
8.6 NERVE STIMULATIONS
9 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.2.1 TABLETS
9.2.1.1 EXTENDED RELEASE
9.2.1.2 IMMEDIATE RELEASE
9.2.2 CAPSULES
9.2.3 OTHERS
9.3 PARENTERAL
9.4 INTRAVESICAL
9.5 TOPICAL
9.6 OTHERS
10 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE
10.1 OVERVIEW
10.2 OVER THE COUNTER
10.3 PRESCRIPTION
11 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULTS
11.3 PEDIATRIC
12 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 PHARMACY STORES
13.3.2 ONLINE RETAIL CHANNEL
13.3.3 OTHERS
13.4 OTHERS
14 EUROPE INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 TURKEY
14.1.7 RUSSIA
14.1.8 NETHERLANDS
14.1.9 SWITZERLAND
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENTS
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 HIKMA PHARMACEUTICALS PLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR. REDDY'S LABORATORIES LTD
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BAYER AG
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 AMNEAL PHARMACEUTICAL LLC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 APOTEX
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 AUROBINDO PHARMA USA
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 AVET PHARMACEUTICALS INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ALVOGEN
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 10.3RECENT DEVELOPMENT
17.11 ACCORD-UK LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 11.3RECENT DEVELOPMENT
17.12 GLAXOSMITHKLINE PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 12.2REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 JOHNSON & JOHNSON SERVICES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 LANNETT
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PRESTIGE CONSUMER HEALTHCARE
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 PFIZER INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 RECKITT BENCKISER GROUP PLC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 STRIDES PHARMA SCIENCE LIMITED.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 VISTA PHARM INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 ZYDUS PHARMACEUTICALS INC.,
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 2 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 3 EUROPE MILD TO MODERATE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE MODERATE TO SEVERE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 EUROPE NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BOTULINUM TOXIN A IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE NERVE STIMULATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE PARENTERAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE INTRAVESICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE TOPICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 33 EUROPE OVER THE COUNTER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE PRESCRIPTION IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE ADULTS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PEDIATRIC IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 EUROPE HOSPITALS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE CLINICS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE HOME HEALTHCARE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 EUROPE DIRECT TENDER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 48 EUROPE INTERSTITIAL CYSTITIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 50 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 EUROPE NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 EUROPE NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 EUROPE ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 EUROPE IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 EUROPE TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 EUROPE ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 EUROPE LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 EUROPE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 EUROPE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 65 EUROPE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 EUROPE TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 68 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 EUROPE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 GERMANY INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 73 GERMANY INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 74 GERMANY MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 GERMANY CELL ANALYZERS IN FLOW CYTOMETRY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 GERMANY ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 GERMANY NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 GERMANY NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 GERMANY ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 GERMANY IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 GERMANY TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 GERMANY OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 GERMANY ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 GERMANY LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 GERMANY BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 GERMANY SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 GERMANY INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 GERMANY ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 GERMANY TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 GERMANY INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 GERMANY INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 GERMANY INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 GERMANY RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 U.K. INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 97 U.K. INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.K. MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.K. ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 U.K. NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 U.K. NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 U.K. ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 U.K. IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 U.K. TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 U.K. OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 U.K. ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 U.K. LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 U.K. BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 U.K. SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 U.K. INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 112 U.K. ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 U.K. TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 114 U.K. INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 115 U.K. INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 116 U.K. INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 117 U.K. INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 118 U.K. RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 119 FRANCE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 120 FRANCE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 FRANCE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 FRANCE ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 FRANCE NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 FRANCE NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 FRANCE IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 FRANCE TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 FRANCE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 FRANCE ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 FRANCE LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 FRANCE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 FRANCE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 FRANCE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 135 FRANCE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 136 FRANCE TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 137 FRANCE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 138 FRANCE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 139 FRANCE INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 FRANCE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 FRANCE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 ITALY INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 143 ITALY INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 ITALY MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 ITALY ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 ITALY NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 ITALY NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 ITALY ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 ITALY IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 ITALY TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 ITALY OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 ITALY ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 ITALY LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 ITALY BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 ITALY SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 ITALY INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 158 ITALY ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 159 ITALY TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 160 ITALY INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 161 ITALY INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 ITALY INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 ITALY INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 164 ITALY RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 SPAIN INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 166 SPAIN INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 SPAIN MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 SPAIN ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 SPAIN NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 SPAIN NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SPAIN ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 SPAIN IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 SPAIN TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 SPAIN OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SPAIN ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SPAIN LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SPAIN BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SPAIN SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SPAIN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 181 SPAIN ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 182 SPAIN TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 183 SPAIN INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 184 SPAIN INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 185 SPAIN INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 186 SPAIN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 187 SPAIN RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 188 TURKEY INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 189 TURKEY INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 190 TURKEY MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 TURKEY ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 TURKEY NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 TURKEY NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 TURKEY ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 TURKEY IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 197 TURKEY TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 TURKEY OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 TURKEY ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 TURKEY LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 TURKEY BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 TURKEY SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 TURKEY INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 204 TURKEY ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 205 TURKEY TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 206 TURKEY INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 207 TURKEY INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 208 TURKEY INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 209 TURKEY INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 210 TURKEY RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 211 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 212 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 RUSSIA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 RUSSIA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 RUSSIA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 RUSSIA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 RUSSIA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 RUSSIA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 RUSSIA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 RUSSIA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 RUSSIA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 RUSSIA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 RUSSIA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 RUSSIA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 227 RUSSIA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 228 RUSSIA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 229 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 230 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 231 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 232 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 233 RUSSIA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 234 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 235 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 236 NETHERLANDS MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 NETHERLANDS ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 238 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 NETHERLANDS NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 240 NETHERLANDS NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 NETHERLANDS ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 NETHERLANDS IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 NETHERLANDS OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 NETHERLANDS ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 NETHERLANDS LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 247 NETHERLANDS BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 248 NETHERLANDS SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 250 NETHERLANDS ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 251 NETHERLANDS TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 252 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 253 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 254 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 255 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 256 NETHERLANDS RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 257 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 258 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 259 SWITZERLAND MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 SWITZERLAND ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 SWITZERLAND NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 SWITZERLAND NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 SWITZERLAND ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 SWITZERLAND IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 266 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SWITZERLAND OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 268 SWITZERLAND ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 269 SWITZERLAND LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 270 SWITZERLAND BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 SWITZERLAND SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 273 SWITZERLAND ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 274 SWITZERLAND TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 275 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 276 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 277 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 278 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 279 SWITZERLAND RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 280 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 281 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 282 BELGIUM MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 283 BELGIUM ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 284 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 285 BELGIUM NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 BELGIUM NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 BELGIUM ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 BELGIUM IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 BELGIUM TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 BELGIUM OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 BELGIUM ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 BELGIUM LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 BELGIUM BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 294 BELGIUM SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 295 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 296 BELGIUM ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 297 BELGIUM TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 298 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 299 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 300 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 301 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 302 BELGIUM RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 303 REST OF EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 EUROPE INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 2 EUROPE INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE INTERSTITIAL CYSTITIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE EUROPE INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE INTERSTITIAL CYSTITIS MARKET
FIGURE 14 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021
FIGURE 15 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029)
FIGURE 17 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021
FIGURE 27 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 29 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 30 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021
FIGURE 31 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 32 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 33 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 34 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021
FIGURE 35 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 40 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029)
FIGURE 47 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
